JonesResearch analyst Justin Walsh downgraded Fusion Pharmaceuticals (FUSN) to Hold from Buy without a price target after the company reached an agreement to be acquired by AstraZeneca (AZN) for an offer price of $21 per share in cash plus a non-transferable contingent value right of $3.00 per share. The firm believes the most likely outcome will be the completion of the acquisition within the targeted Q2 timeframe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FUSN:
- UK Stocks: AstraZeneca (AZN) Expands Cancer Portfolio with Fusion Pharma Acquisition
- Fusion Pharmaceuticals’ Acquisition and Future Focus Shift
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
- Fusion Pharmaceuticals Inc (FUSN) Q4 Earnings Cheat Sheet
- 3 Best Stocks to Buy Now, 3/5/2024, According to Top Analysts
